
    
      Objectives:The primary objective is to compare between treatment groups the cumulative number
      of new gadolinium enhancing (Gd+) lesions on brain MRI at weeks 24, 32, 40 and 48 i n
      subjects with secondary progressive MS. Secondary objectives include additional MRI
      measurements, analyses of clinical relapses, measures of neurologic disability, immunologic
      evaluations, and safety.

      Study Design: Multi-center, randomized , double-blind, placebo-controlled , two arm parallel
      design study of NeuroVax™ vs. Incomplete Freund's Adjuvant ( I F A) placebo.

      Subject Population: 200 subjects with Secondary Progressive SPMS MS, with an EDSS score >=
      3.5 , and meeting all inclusion/exclusion criteria, will be enroll in this study. Subjects
      will be randomized equally to NeuroVax™ or I F A

      ,1 0 0 per arm .
    
  